Citalopram |
Formulary
|
Tablets (as hydrobromide) 10mg, 20mg 8mg oral drops is equivalent to 10mg tablet.
|
MHRA: Citalopram and escitalopram: QT interval prolongation MHRA: Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
Escitalopram |
Formulary
|
Tablets 5mg, 10mg, 20mg Generalised Anxiety Disorder, In depression, escitalopram is only licensed for major depressive episodes. Available for consultant initiation in generalised anxiety disorder but only after sertraline has been tried. |
LSCMMG: Citalopram and escitalopram: QT interval prolongation MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
Fluoxetine |
Formulary
|
Capsules 20mg, First line for children and adolescents. |
MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
Paroxetine |
Formulary
|
Tablets 20mg, 30mg Higher risk of discontinuation reactions. |
MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
Sertraline |
Formulary
|
Tablets 50mg, 100mg LSCFT: Depressive illness, obsessive compulsive disorder (under specialist supervision in children), post traumatic stress disorder, panic disorder, social anxiety disorder. NICE recommend first line for generalised anxiety disorder (unlicensed). |
MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
Vortioxetine Brintellix® |
Formulary
|
Tablets 5mg, 10mg, 20mg Major depressive episodes. |
MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery NICE TA367: Vortioxetine for treating major depressive episodes |
|